{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:48:19Z","timestamp":1780368499962,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12185-024-03866-1","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T04:25:28Z","timestamp":1732508728000},"page":"100-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of stem cell source on secondary steroid for chronic GVHD after allogeneic hematopoietic cell transplantation"],"prefix":"10.1007","volume":"121","author":[{"given":"Kazuhiro","family":"Sanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-7950","authenticated-orcid":false,"given":"Shigeo","family":"Fuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Shingai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayako","family":"Yuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"issue":"9","key":"3866_CR1","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/j.bbmt.2016.05.019","volume":"22","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y, Hirakawa A, Nakasone H, Kurosawa S, Oshima K, Sakai R, et al. Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(9):1702\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2016.05.019.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"3866_CR2","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.bbmt.2016.02.020","volume":"22","author":"Y Matsumura-Kimoto","year":"2016","unstructured":"Matsumura-Kimoto Y, Inamoto Y, Tajima K, Kawajiri A, Tanaka T, Hirakawa T, et al. Association of cumulative steroid dose with risk of infection after treatment for severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22(6):1102\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2016.02.020.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"3866_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00520-020-05572-0","volume":"29","author":"J Cheon","year":"2021","unstructured":"Cheon J, Lee YJ, Jo JC, Kweon K, Koh S, Min YJ, et al. Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2021;29(2):975\u201386. https:\/\/doi.org\/10.1007\/s00520-020-05572-0.","journal-title":"Support Care Cancer"},{"issue":"1","key":"3866_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2021.101253","volume":"34","author":"MED Flowers","year":"2021","unstructured":"Flowers MED. Progress in the management of chronic GVHD insights into novel therapies to treat and manage GVHD lasting longer than 12 Months. Best Pract Res Clin Haematol. 2021;34(1): 101253. https:\/\/doi.org\/10.1016\/j.beha.2021.101253.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"3866_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3324\/haematol.2018.202754","volume":"104","author":"G Fatobene","year":"2019","unstructured":"Fatobene G, Storer BE, Salit RB, Lee SJ, Martin PJ, Cheng GS, et al. Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation. Haematologica. 2019;104(4):835\u201343. https:\/\/doi.org\/10.3324\/haematol.2018.202754.","journal-title":"Haematologica"},{"issue":"4","key":"3866_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s12185-022-03428-3","volume":"116","author":"H Nakamae","year":"2022","unstructured":"Nakamae H. Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide. Int J Hematol. 2022;116(4):465\u201381. https:\/\/doi.org\/10.1007\/s12185-022-03428-3.","journal-title":"Int J Hematol"},{"issue":"8","key":"3866_CR7","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-2004.","journal-title":"Blood"},{"issue":"23","key":"3866_CR8","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664\u201371. https:\/\/doi.org\/10.1182\/blood-2014-01-552984.","journal-title":"Blood"},{"issue":"18","key":"3866_CR9","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1182\/bloodadvances.2019000386","volume":"3","author":"Y Inamoto","year":"2019","unstructured":"Inamoto Y, White J, Ito R, Martin PJ, Fatobene G, Ito A, et al. Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. Blood Adv. 2019;3(18):2764\u201377. https:\/\/doi.org\/10.1182\/bloodadvances.2019000386.","journal-title":"Blood Adv"},{"issue":"8","key":"3866_CR10","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125(8):1333\u20138. https:\/\/doi.org\/10.1182\/blood-2014-10-609032.","journal-title":"Blood"},{"issue":"11","key":"3866_CR11","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53(11):1401\u201315. https:\/\/doi.org\/10.1038\/s41409-018-0204-7.","journal-title":"Bone Marrow Transplant"},{"key":"3866_CR12","doi-asserted-by":"publisher","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I, The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389\u2013401 e1. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001.","DOI":"10.1016\/j.bbmt.2014.12.001"},{"issue":"3","key":"3866_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.497.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"446","key":"3866_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496\u2013509. https:\/\/doi.org\/10.1080\/01621459.1999.10474144.","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"3866_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"3866_CR16","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.bbmt.2020.06.030","volume":"26","author":"J Othman","year":"2020","unstructured":"Othman J, Greenwood M, Moore J, Larsen S, Watson AM, Arthur C, et al. Unrelated donor transplant recipients given thymoglobuline have superior GRFS when compared to matched related donor recipients undergoing transplantation without ATG. Biol Blood Marrow Transplant. 2020;26(10):1868\u201375. https:\/\/doi.org\/10.1016\/j.bbmt.2020.06.030.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"3866_CR17","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S2352-3026(17)30081-9","volume":"4","author":"J Finke","year":"2017","unstructured":"Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L, et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol. 2017;4(6):e293\u2013301. https:\/\/doi.org\/10.1016\/S2352-3026(17)30081-9.","journal-title":"Lancet Haematol"},{"issue":"9","key":"3866_CR18","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1038\/s41409-021-01314-w","volume":"56","author":"S Shiratori","year":"2021","unstructured":"Shiratori S, Sugita J, Fuji S, Aoki J, Sawa M, Ozawa Y, et al. Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant. 2021;56(9):2231\u201340. https:\/\/doi.org\/10.1038\/s41409-021-01314-w.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"3866_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12185-016-1947-9","volume":"103","author":"K Kuriyama","year":"2016","unstructured":"Kuriyama K, Fuji S, Inamoto Y, Tajima K, Tanaka T, Inoue Y, et al. Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation. Int J Hematol. 2016;103(4):453\u201360. https:\/\/doi.org\/10.1007\/s12185-016-1947-9.","journal-title":"Int J Hematol"},{"issue":"5","key":"3866_CR20","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s12185-013-1449-y","volume":"98","author":"S Fuji","year":"2013","unstructured":"Fuji S, Ueno N, Hiramoto N, Asakura Y, Yakushijin K, Kamiyama Y, et al. Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: a single-center retrospective analysis of 103 cases. Int J Hematol. 2013;98(5):608\u201314. https:\/\/doi.org\/10.1007\/s12185-013-1449-y.","journal-title":"Int J Hematol"},{"issue":"3","key":"3866_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.bbmt.2017.10.042","volume":"24","author":"SJ Lee","year":"2018","unstructured":"Lee SJ, Nguyen TD, Onstad L, Bar M, Krakow EF, Salit RB, et al. Success of immunosuppressive treatments in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2018;24(3):555\u201362. https:\/\/doi.org\/10.1016\/j.bbmt.2017.10.042.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"3866_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3324\/haematol.2021.279814","volume":"108","author":"GL Chen","year":"2023","unstructured":"Chen GL, Onstad L, Martin PJ, Carpenter P, Pidala J, Arai S, et al. Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease. Haematologica. 2023;108(2):483\u20139. https:\/\/doi.org\/10.3324\/haematol.2021.279814.","journal-title":"Haematologica"},{"issue":"11","key":"3866_CR23","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.bbmt.2017.08.005","volume":"23","author":"LM Curtis","year":"2017","unstructured":"Curtis LM, Pirsl F, Steinberg SM, Mitchell SA, Baird K, Cowen EW, et al. Predictors for permanent discontinuation of systemic immunosuppression in severely affected chronic graft-versus-host disease patients. Biol Blood Marrow Transplant. 2017;23(11):1980\u20138. https:\/\/doi.org\/10.1016\/j.bbmt.2017.08.005.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3866_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2974","volume":"6","author":"J Pidala","year":"2020","unstructured":"Pidala J, Martens M, Anasetti C, Carreras J, Horowitz M, Lee SJ, et al. Factors associated with successful discontinuation of immune suppression after allogeneic hematopoietic cell transplantation. JAMA Oncol. 2020;6(1): e192974. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2974.","journal-title":"JAMA Oncol"},{"issue":"2","key":"3866_CR25","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1182\/bloodadvances.2019001021","volume":"4","author":"T Ando","year":"2020","unstructured":"Ando T, Tachibana T, Tanaka M, Suzuki T, Ishiyama Y, Koyama S, et al. Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation. Blood Adv. 2020;4(2):408\u201319. https:\/\/doi.org\/10.1182\/bloodadvances.2019001021.","journal-title":"Blood Adv"},{"issue":"8","key":"3866_CR26","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/bloodadvances.2017014464","volume":"2","author":"N Bejanyan","year":"2018","unstructured":"Bejanyan N, Brunstein CG, Cao Q, Lazaryan A, Luo X, Curtsinger J, et al. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv. 2018;2(8):909\u201322. https:\/\/doi.org\/10.1182\/bloodadvances.2017014464.","journal-title":"Blood Adv"},{"issue":"6","key":"3866_CR27","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.bbmt.2012.03.005","volume":"18","author":"Y Fedoriw","year":"2012","unstructured":"Fedoriw Y, Samulski TD, Deal AM, Dunphy CH, Sharf A, Shea TC, et al. Bone marrow B cell precursor number after allogeneic stem cell transplantation and GVHD development. Biol Blood Marrow Transplant. 2012;18(6):968\u201373. https:\/\/doi.org\/10.1016\/j.bbmt.2012.03.005.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3866_CR28","doi-asserted-by":"publisher","unstructured":"Redondo S, Esquirol A, Novelli S, Caballero AC, Garrido A, Onate G et al. Efficacy and safety of ruxolitinib in steroid-refractory\/dependent chronic graft-versus-host disease: real-world data and challenges. Transplant Cell Ther. 2022;28(1):43 e1\u2013e5. https:\/\/doi.org\/10.1016\/j.jtct.2021.10.015.","DOI":"10.1016\/j.jtct.2021.10.015"},{"issue":"21","key":"3866_CR29","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243\u201350. https:\/\/doi.org\/10.1182\/blood-2017-07-793786.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03866-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03866-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03866-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T03:54:40Z","timestamp":1737172480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03866-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3866"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03866-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest associated with this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}